Regenexx® pioneered the treatment of ACL tears with bone marrow concentrate. We have more experience in this procedure than any of our peers across the globe. We also perfected the fluoro-guided perc-ACLR procedure. Our patients’ post-treatment MRIs show healing and outstanding long-term outcomes. About 70% of patients with similar tears would undergo surgery.
We have taken part in ACL clinical studies to share our successes with our perc-ACLR procedure. These two studies, published in 2015 and 2018, are available to physicians and the public to read.
You can see our network of physicians’ outcomes for their patients in the studies linked below.